New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
08:14 EDTGSKGlaxoSmithKline receives EU marketing authorization for Mekinist
GlaxoSmithKline announced Friday that the European Commission has granted marketing authorization for Mekinist as a single agent in the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Trametinib has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy. Before taking trametinib, patients must have confirmation of a BRAF V600 mutation using a validated test. Mekinist was in-licensed by GSK in 2006. GSK holds the worldwide exclusive rights to develop, manufacture and commercialise Mekinist, while Japan Tobacco retains co-promotion rights in Japan.
News For GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
09:21 EDTGSKLigand partner Glaxo files sNDA seeking additional indication for Promacta
Subscribe for More Information
December 18, 2014
09:21 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:15 EDTGSKAgenus reports GSK ZOE-50 Phase 3 study met primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use